This may be important, as BRCA1/2-mutation carriers are potentially at increased CVD risk because of early menopause around age 40 (due to risk-reducing salpingo-oophorectomy), or cardiotoxic effects after adjuvant breast cancer treatment (Arts-de Jong et al. 2014). This evidence concerns the gene BRCA1 and breast cancer.